AU7483000A - Use of mullerian inhibiting substance for treating excess androgen states - Google Patents

Use of mullerian inhibiting substance for treating excess androgen states

Info

Publication number: AU7483000A
Authority: AU; Australia
Prior art keywords: inhibiting substance; treating excess; mullerian inhibiting; excess androgen; states
Prior art date: 1999-09-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU74830/00A

Inventor

Patricia K. Donahoe

Eric Fynn-Thompson

Jose Teixeira

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

General Hospital Corp

Original Assignee

General Hospital Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-14

Filing date

2000-09-14

Publication date

2001-04-17

2000-09-14 Application filed by General Hospital Corp filed Critical General Hospital Corp

2001-04-17 Publication of AU7483000A publication Critical patent/AU7483000A/en

Status Abandoned legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Gynecology & Obstetrics (AREA)
Urology & Nephrology (AREA)
Pregnancy & Childbirth (AREA)
Diabetes (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AU74830/00A 1999-09-14 2000-09-14 Use of mullerian inhibiting substance for treating excess androgen states Abandoned AU7483000A (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US15367499P	1999-09-14	1999-09-14
US60153674		1999-09-14
US15394099P	1999-09-15	1999-09-15
US60153940		1999-09-15
PCT/US2000/025094 WO2001019387A1 (en)	1999-09-14	2000-09-14	Use of mullerian inhibiting substance for treating excess androgen states

Publications (1)

Publication Number	Publication Date
AU7483000A true AU7483000A (en)	2001-04-17

Family

ID=26850750

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU74830/00A Abandoned AU7483000A (en)	1999-09-14	2000-09-14	Use of mullerian inhibiting substance for treating excess androgen states

Country Status (5)

Country	Link
EP (1)	EP1218025A4 (en)
JP (1)	JP2003509377A (en)
AU (1)	AU7483000A (en)
CA (1)	CA2384991A1 (en)
WO (1)	WO2001019387A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HK1222331A1 (en)	2013-03-12	2017-06-30	通用医疗公司	Modified mullerian inhibiting substance (mis) proteins and uses thereof for the treatment of diseases
EP3046582A4 (en)	2013-09-20	2017-05-10	The General Hospital Corporation	Uses of modified mullerian inhibiting substance (mis) proteins for the treatment of neurodegenerative diseases
DK3079712T3 (en)	2013-12-11	2022-04-25	Massachusetts Gen Hospital	USE OF MÜLLER INHIBITANT SUBSTANCE (MIS) PROTEINS FOR CONTRACEPTION AND OVARIAN RESERVE PRESERVATION
US11518793B2 (en)	2016-12-14	2022-12-06	The General Hospital Corporation	Mullerian inhibiting substance (MIS) proteins for ovarian and uterine oncoprotection, and ovarian reserve and uterine preservation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5427780A (en) *	1985-10-30	1995-06-27	Biogen, Inc.	Composition comprising Mullerian inhibiting substance-like polypeptides
US5047336A (en) *	1985-10-30	1991-09-10	Biogen, Inc.	DNA sequences, recombinant DNA molecules and processes for producing mullerian inhibiting substance-like polypeptides
US5484768A (en) *	1990-05-16	1996-01-16	The University Of Melbourne	Treatment of male infertility by administration of a muellerian inhibiting substance and surgery and/or hormonal treatment
AU3920693A (en) *	1992-03-18	1993-10-21	General Hospital Corporation, The	Four novel receptors of the TGF-beta receptor family
JP2947938B2 (en) *	1994-11-28	1999-09-13	旭化成工業株式会社	Optical recording medium

2000
- 2000-09-14 CA CA002384991A patent/CA2384991A1/en not_active Abandoned
- 2000-09-14 JP JP2001523019A patent/JP2003509377A/en active Pending
- 2000-09-14 WO PCT/US2000/025094 patent/WO2001019387A1/en not_active Ceased
- 2000-09-14 EP EP00963414A patent/EP1218025A4/en not_active Withdrawn
- 2000-09-14 AU AU74830/00A patent/AU7483000A/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2001019387A1 (en)	2001-03-22
CA2384991A1 (en)	2001-03-22
EP1218025A4 (en)	2005-06-01
JP2003509377A (en)	2003-03-11
EP1218025A1 (en)	2002-07-03

Publication	Publication Date	Title
AU7906100A (en)	2001-04-30	Use of retigabin for treating neuropathic pain
AU5696200A (en)	2001-01-22	Method for treatment of underground reservoirs
GB2364725B (en)	2003-06-25	Method for treatment of underground reservoirs
AU6528800A (en)	2001-04-24	Methods and apparatuses for radiation treatment
HU0001471D0 (en)	2000-06-28	New method of treatment
EP1176964B8 (en)	2007-10-10	Uses of et743 for treating cancer
AU2000258650A1 (en)	2001-11-20	2-piperidone compounds for the treatment of cancer
AU4213299A (en)	2000-12-18	Controlled release of substances
AU2001228703A1 (en)	2001-08-14	Use of cox-2 inhibitors for the treatment of constipation
AU2512501A (en)	2001-07-09	Use of trimebutine for treating pain
AU7363000A (en)	2001-04-24	Method for reducing the risk of cancer
AU7483000A (en)	2001-04-17	Use of mullerian inhibiting substance for treating excess androgen states
AU2566201A (en)	2001-07-09	Compounds and methods for the treatment of pain
AU5552400A (en)	2001-01-09	Treatment of cancer
AUPQ367699A0 (en)	1999-11-18	Treatment of cancer
AU1036801A (en)	2001-04-30	Agent for treating cephalic pain
AU4157600A (en)	2000-10-16	Machine for treatment of plate-shaped objects
AU5824800A (en)	2001-01-31	Use of fosphenytoin for the treatment of acute neuropathic pain
AU4021700A (en)	2000-10-09	Methods of use of beta1-integrin inhibitors
EP1135141A4 (en)	2003-03-05	Phospholipase inhibitors for the treatment of cancer
AU6979800A (en)	2001-01-30	Device and method for the partial electrochemical treatment of bar-shaped elements
AUPQ136699A0 (en)	1999-07-22	Method for treatment of cancer and compositions for use therein
AUPP872299A0 (en)	1999-03-11	Treatment of bunions
AU1882000A (en)	2000-08-07	Treatment of nicotine dependency
AUPQ080999A0 (en)	1999-06-24	Method of treatment

Legal Events

Date	Code	Title	Description
2002-05-16	MK6	Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase